Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
The financial performance from 2017 through 2021 is characterized by a significant growth phase peaking in 2019, followed by a pronounced downward trajectory. Both reported and adjusted net income attributable to the company exhibited nearly identical movements, indicating that the adjustments made for mark-to-market available-for-sale securities had a minimal impact on the overall bottom-line results.
- Net Income Trends
- Reported net income demonstrated a strong upward trend in the first three years, rising from 2,539,100 thousand USD in 2017 to a peak of 5,888,500 thousand USD in 2019. This growth was followed by a sharp decline, with earnings dropping to 4,000,600 thousand USD in 2020 and further decreasing to 1,556,100 thousand USD by December 31, 2021.
- Analysis of Adjustments
- The variance between reported and adjusted net income remained negligible relative to the total income figures. In 2017 and 2019, adjusted net income was slightly higher than reported net income, suggesting positive mark-to-market adjustments. In contrast, 2018, 2020, and 2021 saw reported net income slightly exceeding adjusted net income, indicating negative adjustments during those periods.
- Impact of Mark-to-Market Securities
- The magnitude of the adjustments is low, with the maximum difference occurring in 2017 at 9,200 thousand USD. The consistency between the reported and adjusted figures suggests that fluctuations in the fair value of available-for-sale securities did not materially distort the operational profitability or the broader financial trend of the organization over the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Biogen Inc., Profitability Ratios: Reported vs. Adjusted
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Profitability and efficiency metrics exhibited a synchronized trajectory from 2017 through 2021, reaching a zenith in 2019 before undergoing a marked contraction. The correlation between reported and adjusted values is nearly absolute, suggesting that the adjustments related to mark-to-market available-for-sale securities were immaterial to the primary financial performance ratios.
- Net Profit Margin Analysis
- The net profit margin experienced substantial growth in the first three years, rising from 20.69% in 2017 to a peak of 40.96% in 2019. This upward trend reversed sharply thereafter, falling to 29.76% in 2020 and further declining to 14.17% by the end of 2021, representing a significant reduction in the proportion of revenue retained as profit.
- Return on Equity (ROE) Trends
- ROE followed a similar bell-shaped curve, increasing from 20.13% in 2017 to a high of 44.13% in 2019. While the decline in 2020 was more moderate at 37.39%, a steep drop occurred in 2021, with the ratio falling to 14.28%, indicating a decrease in the efficiency of generating profits from shareholders' equity.
- Return on Assets (ROA) Performance
- Asset utilization efficiency improved significantly between 2017 and 2019, with the reported ROA climbing from 10.73% to 21.62%. This metric deteriorated steadily over the following two years, ending at 6.52% in 2021, which constitutes the lowest point recorded within the five-year period.
- Variance Between Reported and Adjusted Figures
- A comparison between reported and adjusted ratios reveals negligible variance across all measured categories. For example, the difference in the adjusted versus reported net profit margin in 2019 was only 0.05 percentage points. This consistency indicates that mark-to-market fluctuations of available-for-sale securities did not materially distort the reported profitability or operational efficiency of the entity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
2021 Calculations
1 Net profit margin = 100 × Net income attributable to Biogen Inc. ÷ Revenue
= 100 × 1,556,100 ÷ 10,981,700 = 14.17%
2 Adjusted net profit margin = 100 × Adjusted net income attributable to Biogen Inc. ÷ Revenue
= 100 × 1,552,500 ÷ 10,981,700 = 14.14%
The analysis of profitability metrics reveals a cyclical trend in net profit margins over the five-year period ending December 31, 2021. A period of significant growth in profitability was observed between 2017 and 2019, followed by a marked contraction through 2021.
- Adjusted Net Profit Margin Trend
- The adjusted net profit margin experienced an upward trajectory from 20.76% in 2017 to a peak of 41.01% in 2019. This expansion indicates a substantial increase in the efficiency of converting revenue into profit. However, this trend reversed starting in 2020, with the margin falling to 29.74%, and continuing a sharp decline to 14.14% by the end of 2021.
- Adjusted Net Income Performance
- Adjusted net income followed a parallel pattern to the profit margin, rising from approximately 2.55 billion US$ in 2017 to a maximum of 5.90 billion US$ in 2019. The subsequent decrease was significant, with net income dropping to 4.00 billion US$ in 2020 and further plummeting to 1.55 billion US$ in 2021, representing a substantial contraction in absolute earnings from the 2019 peak.
- Correlation Between Reported and Adjusted Metrics
- A high degree of convergence is observed between the reported and adjusted net profit margins across all five years. The minimal variance between these figures suggests that non-recurring items and adjustments had a negligible impact on the overall profitability profile, indicating that the observed fluctuations are driven by core operational performance rather than one-time accounting adjustments.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
2021 Calculations
1 ROE = 100 × Net income attributable to Biogen Inc. ÷ Total Biogen Inc. shareholders’ equity
= 100 × 1,556,100 ÷ 10,896,200 = 14.28%
2 Adjusted ROE = 100 × Adjusted net income attributable to Biogen Inc. ÷ Total Biogen Inc. shareholders’ equity
= 100 × 1,552,500 ÷ 10,896,200 = 14.25%
The financial performance from 2017 to 2021 exhibits a cyclical trajectory, characterized by a period of strong growth in profitability and equity efficiency peaking in 2019, followed by a significant contraction through 2021.
- Adjusted Net Income Trends
- Adjusted net income grew steadily from US$ 2,548,300 thousand in 2017 to a peak of US$ 5,896,700 thousand in 2019. This growth trend reversed after 2019, with a decline to US$ 3,997,800 thousand in 2020 and a further reduction to US$ 1,552,500 thousand by the end of 2021.
- Adjusted Return on Equity (ROE) Performance
- The Adjusted ROE mirrors the trajectory of net income, increasing from 20.20% in 2017 to a maximum of 44.19% in 2019. This peak represents the highest level of capital efficiency in the analyzed period. Subsequently, the ratio declined to 37.36% in 2020 and experienced a sharp decrease to 14.25% in 2021, falling below the initial 2017 levels.
- Analysis of Reported versus Adjusted Metrics
- A minimal variance is observed between reported and adjusted figures for both net income and ROE across the five-year span. The proximity of these values indicates that non-recurring items and other adjustments had a negligible impact on the overall interpretation of the company's profitability and its return on shareholder equity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
2021 Calculations
1 ROA = 100 × Net income attributable to Biogen Inc. ÷ Total assets
= 100 × 1,556,100 ÷ 23,877,300 = 6.52%
2 Adjusted ROA = 100 × Adjusted net income attributable to Biogen Inc. ÷ Total assets
= 100 × 1,552,500 ÷ 23,877,300 = 6.50%
The financial performance between 2017 and 2021 is characterized by a period of significant expansion in profitability and asset efficiency followed by a sharp contraction.
- Adjusted Net Income Trends
- Adjusted net income exhibited a strong growth trajectory in the early part of the period, rising from US$ 2,548,300 thousand in 2017 to a peak of US$ 5,896,700 thousand in 2019. This growth was followed by a substantial decline, with income falling to US$ 3,997,800 thousand in 2020 and further decreasing to US$ 1,552,500 thousand by December 31, 2021.
- Adjusted Return on Assets (ROA) Analysis
- The Adjusted ROA mirrored the trend of net income, demonstrating a peak in asset productivity in 2019 at 21.65%. Prior to this, the ratio climbed from 10.77% in 2017 to 17.50% in 2018. A downward trend emerged thereafter, with the ratio receding to 16.24% in 2020 and dropping to 6.50% in 2021, indicating a marked reduction in the company's ability to generate earnings from its asset base.
- Correlation Between Reported and Adjusted Metrics
- There is a high degree of convergence between reported and adjusted figures throughout the five-year period. The variance between reported ROA and adjusted ROA is minimal, with differences often remaining within 0.03 percentage points. This suggests that non-recurring items or adjustments had a negligible impact on the overall interpretation of the company's asset utilization and profitability.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?